RecruitingPhase 2NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Studying ALK-positive large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
- Principal Investigator
- Matthew Frigault, MDMassachusetts General Hospital
- Intervention
- Emapalumab(drug)
- Enrollment
- 28 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (2)
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06550141 on ClinicalTrials.govOther trials for ALK-positive large B-cell lymphoma
Additional recruiting or active studies for the same condition.